Vnitr Lek 2010, 56(8):795-800

Primary central nervous system lymphomas

M. Hrudková*, D. Belada, L. Smolej, P. Žák, J. Malý
Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal lymphoma (nearly always non-Hodgkin's) and accounts for approximately 3 to 4% of primary brain tumors. PCNSL typically affects patients older than 60 years. Clinical features are variable and reflect the location of central nervous system lesion. Magnetic resonance imaging and stereotactic biopsy are the most important tools for diagnostic assessment. Chemotherapy based on high-dose of methotrexate (HD-MTX) and whole brain radiotherapy are the cornerstones of treatment. Radiotherapy is usually omitted in individuals older than 60 years because of high risk of unacceptable delayed neurotoxicity. Treatment of PCNSL should be started as soon as possible after diagnosis because delay in treatment may shorten the patients' survival.

Keywords: primary central nervous system lymphoma; chemotherapy; methotrexate; radiotherapy; neurotoxicity

Received: October 9, 2009; Accepted: March 7, 2010; Published: August 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrudková M, Belada D, Smolej L, Žák P, Malý J. Primary central nervous system lymphomas. Vnitr Lek. 2010;56(8):795-800.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kluin PM, Ko YH, Kovrigina AM et al. World Health Organisation classification of tumors of haematopoietic and lymphoid tissue. Lyon: IARC Press 2008.
    2. Singh AD, Lewis H, Schachat AP. Primary lymphoma of the central nervous system. Ophthalmol Clin North Am 2005; 18: 199-207. Go to original source... Go to PubMed...
    3. Hoang-Xuan K, Camilleri-Broët S, Soussain C. Recent advances in primary CNS lymphoma. Curr Opin Oncol 2004; 16: 601-606. Go to original source... Go to PubMed...
    4. Hochberg FH, Baehring JM, Hochberg EP. Primary CNS lymphoma. Nat Clin Pract Neurol 2007; 3: 24-35. Go to original source... Go to PubMed...
    5. Commins DL. Pathology of primary central nervous system lymphoma. Neurosurg Focus 2006; 21: E2. Go to original source... Go to PubMed...
    6. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006; 24: 1281-1288. Go to original source... Go to PubMed...
    7. Fitzsimmons A, Upchurch K, Batchelor T. Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 689-703. Go to original source... Go to PubMed...
    8. Eichler AF, Batchelor TT. Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus 2006; 21: E15. Go to original source... Go to PubMed...
    9. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009; 8: 581-592. Go to original source... Go to PubMed...
    10. Říhová E, Šišková A, Jandusová J et al. Nitrooční lymfom - klinická studie14 pacientů s NHL. Cesk Slov Oftalmol 2004; 60: 3-16. Go to PubMed...
    11. Ferreri AJ, Reni M. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2007; 63: 257-268. Go to original source... Go to PubMed...
    12. Almhanna K, Wongchaowart N, Sweetenham J. Intracerebral Hodgkin's lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest 2009; 27: 215-220. Go to original source... Go to PubMed...
    13. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-272. Go to original source... Go to PubMed...
    14. Go JL, Lee SC, Kim PE. Imaging of primary central nervous system lymphoma. Neurosurg Focus 2006; 21: E4. Go to original source... Go to PubMed...
    15. Mohile NA, DeAngelis LM, Abrey LE. Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 2008; 6: 818-820.
    16. Gerstner E, Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther 2007; 7: 689-700. Go to original source... Go to PubMed...
    17. Klabusay M, Pevná M, Kissová J et al. Vzácná diagnóza: CD4+56+ leukémie z dendritických buněk typu DC2. Čas Lék Česk 2009; 147: 511-515.
    18. Shah GD, DeAngelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 611-627. Go to original source... Go to PubMed...
    19. Ferreri AJ, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am 2005; 19: 629-649. Go to original source... Go to PubMed...
    20. Cady FM, O'Neill BP, Law ME et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 2008; 26: 4814-4819. Go to original source... Go to PubMed...
    21. Tun HW, Personett D, Baskerville KA et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111: 3200-3210. Go to original source... Go to PubMed...
    22. DeAngelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 2004; 31: 684-692. Go to original source... Go to PubMed...
    23. DeAngelis LM, Iwamoto FM. An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2006: 311-316. Go to original source... Go to PubMed...
    24. Abrey LE. Controversies in primary CNS lymphoma. Expert Rev Neurother 2005; 5: 459-464. Go to original source... Go to PubMed...
    25. Lachance DH, Brizel DM, Gockerman JP et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 1994; 44: 1721-1727. Go to original source... Go to PubMed...
    26. Schultz C, Scott C, Sherman W et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996; 14: 556-564. Go to original source... Go to PubMed...
    27. Ekenel M, Iwamoto FM, Ben-Porat LS et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 2008; 113: 1025-1031. Go to original source... Go to PubMed...
    28. Bessell EM, López-Guillermo A, Villá S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20: 231-236. Go to original source...
    29. Belada D, Smolej L, Štěpanková P et al. Dosažení Bcl-2/IgH negativity v periferní krvi/kostní dřeni po léčbě je u nemocných s folikulárním lymfomem spojeno s lepší prognózou onemocnění. Vnitř Lék 2007; 53: 1057-1063. Go to PubMed...
    30. Soussain C, Hoang-Xuan K, Doolittle ND. New treatment approaches in primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 719-728. Go to original source... Go to PubMed...
    31. Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730-4735. Go to original source... Go to PubMed...
    32. Hong SJ, Kim JS, Chang JH et al. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Med J 2009; 50: 280-283. Go to original source... Go to PubMed...
    33. Aboulafia DM, Ratner L, Miles SA et al. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma 2006; 6: 399-402. Go to original source... Go to PubMed...
    34. Kreisl TN, Panageas KS, Elkin EB et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma 2008; 49: 1710-1716. Go to original source... Go to PubMed...
    35. Parekh S, Ratech H, Sparano JA. Human immunodeficiency virus-associated lymphoma. Clin Adv Hematol Oncol 2003; 1: 295-301.
    36. Belada D, Trněný M, Campr V et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy III. 4th ed. Hradec Králové: HK Credit 2009: 30-36.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.